埃罗替尼的疗效与其所致皮疹的相关性

Relationship between efficacy and erlotinib-induced rash

埃罗替尼为表皮生长因子受体酪氨酸激酶抑制剂,用作局部晚期或转移性非小细胞肺癌的二、三线治疗。埃罗替尼常见不良反应为痤疮样皮疹和腹泻。皮疹的发生率为61.7%～82.0%,主要分布在面部、颈部及躯干。接受埃罗替尼治疗的患者通常在治疗后1周左右发生皮疹,2～3周皮疹最严重,大多数患者的皮疹在第4周消退,但某些患者的皮疹会持续较长的时间。临床试验显示:皮疹和剂量相关;发生严重皮疹患者的生存期比轻度或未发生皮疹患者长。因此,皮疹可作为埃罗替尼有效治疗肺癌的预测指标。

Erlotinib is a tyrosine kinase inhibitor of epidermal growth factor receptor. It is used in second-and third-line treatment of patients with locally advanced or metastatic non-small cell lung cancer. The common adverse reactions to erlotinib are acneiform skin rash and diarrhea. The incidence of rash is 61.2% - 82.0%. Typically, the rash involved the face, neck, and trunk, Rash onset is usually about 1 week after starting therapy, with maximal intensity in the second or third week. It usually subsides by week 4 in most patients, although it does persist for longer periods in a few patients. Clinical trial shows that the rash is dose-related, and overall survival in the patients who develop a moderate to severe rash is longer than the patients who have a mild rash or none at all. Development of an erlotinib-associated rash may be an indicator that the drug is effective in treatment of lung cancer.